메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder

SHANGHAI, Feb. 24, 2026 -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Haier Financial Holdings have been formally acquired by existing shareholder Shanghai Liferiver Biotechnology Co., Ltd. ("Liferiver Biotech") and new strategic investor Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. ("Yanghe Investment"). The restructuring is designed t
- 김갑성 기자
- 2026-02-24 22:00
Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

[ 메디채널 김갑성 기자 ] A strategic combination of the Florida SMA hub, Benco Dental's network, SCHEU alliance, and FUGO's multi-resin platform drives a global scale-up. Florida Production Hub: Establishing a domestic manufacturing base to provide localized, order-based SMA solutions for U.S. clinicians. Benco Dental Partnership: Unlocking a massive distribution network covering over 30,000 dental offices (23% of the U.S. market). Strategic Alliance with SCHEU Group: Partnering with Germany's century-old industry leader to validate SMA technology and expand European market share.Introd
- 김갑성 기자
- 2026-02-24 22:00
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

HAMILTON, ON, Feb. 24, 2026 -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing. The Phase 1/2a clinical study is designed as a dose
- 김갑성 기자
- 2026-02-24 22:00
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

[ 메디채널 김갑성 기자 ] 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 24, 2026 -- On February 23, Illumina, Inc. (NASDAQ: ILMN) unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and outp
- 김갑성 기자
- 2026-02-24 19:36
Fat or Skinny Fat: Both Can Harm Your Health | Join the Anti-Obesity Health Base: Outsmart the Obesity Threat Together

HONG KONG, Feb. 24, 2026 -- Hong Kong is a world-renowned food paradise, offering everything from local snacks like fish balls and egg waffles to Michelin-starred culinary experiences. However, maintaining a healthy weight amidst fast-paced lifestyles, high pressure, and even genetic factors has become a relentless battle. Excessive fat accumulation poses significant health risks, and even those with a seemingly slender physique can fall into the trap of obesity. Today, obesity is no longer just a cosmetic concern; it is classified as a chronic, relapsing disease by the World Health Organizat
- 김갑성 기자
- 2026-02-24 16:30
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China

HANGZHOU, China, Feb. 24, 2026 -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authorization Holder and will be responsible for research and d
- 김갑성 기자
- 2026-02-24 13:14
HSI Donesafe and Neopharma Technologies Announce API Integration for Fit-For-Duty Workflows

SYDNEY, Feb. 24, 2026 -- Many organisations have invested heavily in safety management systems, yet Fit-For-Duty controls are still handled separately or measured inconsistently. Drug and alcohol programs often sit outside core safety platforms, while functional impairment from fatigue, illness, stress, or psychosocial hazards is rarely assessed routinely or recorded in a consistent, auditable way. HSI Donesafe and Neopharma Technologies Ltd today announced a partnership to close this gap by embedding Fit-For-Duty workflows directly into the Donesafe platform.&nbs
- 김갑성 기자
- 2026-02-24 09:10
NYSE Content Update: Stock Market to Open Like Normal Amid Historic NYC Blizzard

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 23, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. John Deere will preview CONEXPO on NYSE Live Ashley Mastronardi delivers the pre-market update on February 23rd The New York Stock Exchange and equities markets will open today, as normal, despite the Northeast being hit by a historic winter blizzard. Leaders from
- 황정호 기자
- 2026-02-23 22:04
ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options

Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate – whether as a standalone cloud application or as an integrated extension of ZEISS FORUM – enabling secure data sharing, structured referrals, and real-time clinical coordination to strengthen continuity of care across the ophthalmic workflow. JENA, Germany, Feb. 23, 2026 -- ZEISS Medical Technology, one of the world's leading medical technology companies, today launched its ZEISS Collaborative Care browser-based software application enabling eye care pr
- 김갑성 기자
- 2026-02-23 22:00
"Would You Clone Yourself for a Cure?" Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using 'Human Cloning' Technology

Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 -- Human cloning has long been a subject of dystopian science fiction and a stringent ethical taboo. However, Clonell Therapeutics, Inc., a cutting-edge biotechnology company, is actively shaking the landscape of regenerative medicine by bringing this powerful, historically controversial technology into the clinical setting in
- 김갑성 기자
- 2026-02-23 21:40

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분